centhaquine
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
1
Earliest trial started May 29, 2017 (NCT04056065)
Timeline
Indications
Approved for
Mechanism of action
- Beta-2 adrenergic receptorINHIBITOR
ADRB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(N2CCN(CCc3ccc4ccccc4n3)CC2)c1- Mol. weight
- 331.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594437 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05251181 | Phase 3 | Dec 31, 2022 | Pharmazz, Inc. |
| NCT05241067 | Phase 2 | Oct 31, 2022 | Pharmazz, Inc. |
| NCT05956418 | Phase 4 | Aug 13, 2021 | Pharmazz, Inc. |
| NCT04045327 | Phase 3 | Jan 31, 2019 | Pharmazz, Inc. |
| NCT04056065 | Phase 2 | May 29, 2017 | Pharmazz, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharmazz, Inc. | For profit | 5 | 5 | 3 | 2017 |
1 organizations
Page 1 / 1